The Impact of Age on Survival in CLL Patients Receiving Ibrutinib as Initial Therapy

INTRODUCTION: Recent randomized trials have demonstrated the efficacy of ibrutinib-based therapy in the treatment of patients with CLL. In Alliance A041202, a higher than expected number of unexplained deaths were reported with front-line ibrutinib in a patient population aged at least 65 years comp...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood Lymphat Cancer
Main Authors: Ujjani, Chaitra, Mato, Anthony, Hill, Brian T, Allan, John N, Lansigan, Frederick, Jacobs, Ryan, Skarbnik, Alan, Tuncer, Hande, Pagel, John, Brander, Danielle, Cheson, Bruce, Barr, Paul, Roeker, Lindsey E, Pu, Jeffrey, Shah, Nirav N, Goy, Andre, Schuster, Stephen J, Lamanna, Nicole, Sehgal, Alison, Tam, Constantine S, Shadman, Mazyar
Formato: Artigo
Idioma:Inglês
Publicado em: Dove 2020
Assuntos:
Original Research
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7473982/
https://ncbi.nlm.nih.gov/pubmed/32943973
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/BLCTT.S262592
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados